Exposure to proton pump inhibitors and risk of pancreatic cancer: a meta-analysis
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Exposure to proton pump inhibitors and risk of pancreatic cancer: a meta-analysis
Authors
Keywords
-
Journal
Expert Opinion On Drug Safety
Volume -, Issue -, Pages 1-8
Publisher
Informa UK Limited
Online
2020-01-11
DOI
10.1080/14740338.2020.1715939
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment - a nationwide population-based study
- (2019) Yu-Hung Fang et al. Cancer Management and Research
- Association between proton pump inhibitors and the risk of hepatocellular carcinoma
- (2018) Y.-H. J. Shao et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Updated meta-analysis of controlled observational studies: proton-pump inhibitors and risk of Clostridium difficile infection
- (2018) F. Cao et al. JOURNAL OF HOSPITAL INFECTION
- Use of proton pump inhibitors and risk of pancreatic cancer
- (2018) Blánaid Hicks et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Association between proton pump inhibitor use and the risk of pancreatic cancer: A Korean nationwide cohort study
- (2018) In Cheol Hwang et al. PLoS One
- Proton Pump Inhibitor Use is Associated With Risk of Pancreatic Cancer: A Nested Case–Control Study
- (2018) Yen-Chun Peng et al. Dose-Response
- Proton pump inhibitors therapy and risk of bone diseases: An update meta-analysis
- (2018) Jian Liu et al. LIFE SCIENCES
- Risk and protective factors for the occurrence of sporadic pancreatic endocrine neoplasms
- (2017) Roberto Valente et al. ENDOCRINE-RELATED CANCER
- A Clinical Prediction Model to Assess Risk for Pancreatic Cancer Among Patients With New-Onset Diabetes
- (2017) Ben Boursi et al. GASTROENTEROLOGY
- Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies
- (2015) S. E. Attwood et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Detectable Symptomatology Preceding the Diagnosis of Pancreatic Cancer and Absolute Risk of Pancreatic Cancer Diagnosis
- (2015) H. A. Risch et al. AMERICAN JOURNAL OF EPIDEMIOLOGY
- Proton pump inhibitors and risk of periampullary cancers-A nested case-control study
- (2015) Li-Nien Chien et al. INTERNATIONAL JOURNAL OF CANCER
- Enduring and Emerging Challenges of Informed Consent
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Ulcer, gastric surgery and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case–Control Consortium (PanC4)
- (2013) C. Bosetti et al. ANNALS OF ONCOLOGY
- Acid suppressive drugs and gastric cancer: A meta-analysis of observational studies
- (2013) Jeong Soo Ahn WORLD JOURNAL OF GASTROENTEROLOGY
- Proton pump inhibitors and histamine-2-receptor antagonists and pancreatic cancer risk: a nested case–control study
- (2011) M C Bradley et al. BRITISH JOURNAL OF CANCER
- Proton-Pump Inhibitor as Palliative Care for Chemotherapy-Induced Gastroesophageal Reflux Disease in Pancreatic Cancer Patients
- (2010) Tadashi Uwagawa et al. JOURNAL OF PALLIATIVE MEDICINE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started